HK1060523A1 - Oral dosage self-emulsifying formulations of pyranone protease inhibitors - Google Patents

Oral dosage self-emulsifying formulations of pyranone protease inhibitors

Info

Publication number
HK1060523A1
HK1060523A1 HK04103585A HK04103585A HK1060523A1 HK 1060523 A1 HK1060523 A1 HK 1060523A1 HK 04103585 A HK04103585 A HK 04103585A HK 04103585 A HK04103585 A HK 04103585A HK 1060523 A1 HK1060523 A1 HK 1060523A1
Authority
HK
Hong Kong
Prior art keywords
oral dosage
protease inhibitors
pyranone protease
emulsifying formulations
pyranone
Prior art date
Application number
HK04103585A
Other languages
English (en)
Inventor
Shirlynn Chen
Jocelyn A Gunn
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of HK1060523A1 publication Critical patent/HK1060523A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Pyrane Compounds (AREA)
HK04103585A 2000-10-31 2004-05-20 Oral dosage self-emulsifying formulations of pyranone protease inhibitors HK1060523A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24443400P 2000-10-31 2000-10-31
PCT/US2001/048683 WO2002036110A2 (en) 2000-10-31 2001-10-30 Oral self-emulsifying formulations of pyranone protease inhibitors

Publications (1)

Publication Number Publication Date
HK1060523A1 true HK1060523A1 (en) 2004-08-13

Family

ID=22922748

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04103585A HK1060523A1 (en) 2000-10-31 2004-05-20 Oral dosage self-emulsifying formulations of pyranone protease inhibitors

Country Status (30)

Country Link
US (1) US6555558B2 (xx)
EP (1) EP1333810B1 (xx)
JP (1) JP4298998B2 (xx)
KR (1) KR100847679B1 (xx)
CN (1) CN1240437C (xx)
AT (1) ATE381922T1 (xx)
AU (2) AU2002230918B2 (xx)
BG (1) BG107728A (xx)
BR (1) BR0114969A (xx)
CA (1) CA2424596C (xx)
CZ (1) CZ20031407A3 (xx)
DE (1) DE60132103T2 (xx)
DK (1) DK1333810T3 (xx)
EA (1) EA006759B1 (xx)
EC (1) ECSP034572A (xx)
EE (1) EE200300201A (xx)
ES (1) ES2298286T3 (xx)
HK (1) HK1060523A1 (xx)
HR (1) HRP20030339A2 (xx)
HU (1) HUP0301487A2 (xx)
IL (2) IL154983A0 (xx)
MX (1) MXPA03003795A (xx)
NO (1) NO20031909L (xx)
NZ (1) NZ526169A (xx)
PL (1) PL365627A1 (xx)
SK (1) SK6572003A3 (xx)
UA (1) UA78689C2 (xx)
WO (1) WO2002036110A2 (xx)
YU (1) YU32103A (xx)
ZA (1) ZA200302389B (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1708680A2 (en) * 2004-01-21 2006-10-11 Janssen Pharmaceutica N.V. Mitratapide oral solution
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
JP4373427B2 (ja) * 2005-11-15 2009-11-25 エフ．ホフマン−ラ ロシュ アーゲー 電気的滴下監視
EP1957053A4 (en) * 2005-11-17 2012-03-28 Bioavailability Inc BIOKOMPATIBLE LATENT EMULSIFICATORS
ES2363452T3 (es) * 2006-07-06 2011-08-04 Ares Trading S.A. Una composición farmacéutica oral de una anilinopirimidina, su preparación y uso de la misma.
CN101702878B (zh) * 2007-05-11 2012-11-28 弗·哈夫曼-拉罗切有限公司 可溶性差的药物的药物组合物
US20100152244A1 (en) * 2007-05-23 2010-06-17 Boehringer Ingelheim International Gmbh Self-emulsifying formulation of tipranavir for oral administration
WO2009084036A2 (en) * 2007-12-20 2009-07-09 Matrix Laboratories Limited Composition for treatment of viral infections
WO2012010942A2 (en) * 2010-07-22 2012-01-26 Lupin Limited Novel pharmaceutical composition(s) of hiv protease inhibitor(s)
MY158809A (en) * 2010-09-22 2016-11-15 Craun Res Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
US20130302414A1 (en) * 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
AU2014210103B2 (en) 2013-01-22 2018-09-06 F. Hoffmann-La Roche Ag Pharmaceutical composition with improved bioavailability
US20160000799A1 (en) 2013-02-21 2016-01-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
CA2987272C (en) 2015-05-28 2019-08-20 Dr. Reddy's Laboratories Ltd. Oral composition of celecoxib for treatment of pain
RU2019110875A (ru) 2016-09-13 2020-10-15 Аллерган, Инк. Небелковые композиции клостридиального токсина

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2308955T5 (es) * 1993-09-28 2012-04-03 R.P. Scherer Gmbh Fabricación de cápsulas de gelatina blanda
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
KR0167613B1 (ko) * 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
US6008228A (en) * 1995-06-06 1999-12-28 Hoffman-La Roche Inc. Pharmaceutical compositions containing proteinase inhibitors
DK0989851T3 (da) * 1997-07-29 2003-01-27 Upjohn Co Selvemulgerende formulering indeholdende sure lipofile forbindelser
EP0999838B1 (en) * 1997-07-29 2002-04-03 PHARMACIA & UPJOHN COMPANY Self-emulsifying formulation for lipophilic compounds
US6147095A (en) * 1998-11-04 2000-11-14 Pharmacia & Upjohn Company Method for improving the pharmacokinetics of tipranavir

Also Published As

Publication number Publication date
KR20030048097A (ko) 2003-06-18
DE60132103T2 (de) 2008-04-17
NO20031909L (no) 2003-05-22
IL154983A0 (en) 2003-10-31
WO2002036110A3 (en) 2003-05-08
NO20031909D0 (no) 2003-04-29
ES2298286T3 (es) 2008-05-16
DK1333810T3 (da) 2008-02-04
BR0114969A (pt) 2003-12-09
SK6572003A3 (en) 2003-10-07
HUP0301487A2 (hu) 2003-11-28
UA78689C2 (en) 2007-04-25
YU32103A (sh) 2006-05-25
AU3091802A (en) 2002-05-15
IL154983A (en) 2006-12-31
CZ20031407A3 (cs) 2003-09-17
KR100847679B1 (ko) 2008-07-23
BG107728A (bg) 2004-01-30
MXPA03003795A (es) 2003-08-20
CA2424596A1 (en) 2002-05-10
NZ526169A (en) 2005-12-23
ZA200302389B (en) 2004-04-23
CN1240437C (zh) 2006-02-08
US20020115690A1 (en) 2002-08-22
ECSP034572A (es) 2003-05-26
EP1333810A2 (en) 2003-08-13
WO2002036110A9 (en) 2003-09-18
JP2004512362A (ja) 2004-04-22
DE60132103D1 (de) 2008-02-07
PL365627A1 (en) 2005-01-10
EA200300481A1 (ru) 2003-10-30
CN1471387A (zh) 2004-01-28
US6555558B2 (en) 2003-04-29
AU2002230918B2 (en) 2006-12-14
EP1333810B1 (en) 2007-12-26
JP4298998B2 (ja) 2009-07-22
WO2002036110A2 (en) 2002-05-10
ATE381922T1 (de) 2008-01-15
HRP20030339A2 (en) 2005-04-30
CA2424596C (en) 2010-06-29
EA006759B1 (ru) 2006-04-28
EE200300201A (et) 2003-08-15

Similar Documents

Publication Publication Date Title
ZA200302389B (en) Oral dosage self-emulsifying formulations of pyranone protease inhibitors.
HK1257502A1 (zh) 一種包含hiv蛋白酶抑制劑固體分散體的固體藥物劑型
DK0732923T3 (da) Farmaceutiske sammensætninger indeholdende HIV-proteaseinhibitorer
BG103425A (en) Pharmaceutical composition
HK1120213A1 (en) Improved hiv protease inhibitors pharmaceutical formulations
NO984386L (no) Blandinger omfattende en HIV-protease-inhibitor sÕ som VX 478 og en vannl°selig vitamin E-forbindelse sÕ som vitamin E-TPG'er
MX9602984A (es) Composiciones farmaceuticas que contienen inhibidores de proteasa de vih.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20091030